Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

被引：12

作者：

Kyaw, Moe H. H. ^{[1
]}

Spinardi, Julia ^{[2
]}

Zhang, Ling ^{[3
]}

Oh, Helen May Lin ^{[4
]}

Srivastava, Amit ^{[5
]}

机构：

[1] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Gaithersburg, MD USA

[2] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Sao Paulo, Brazil

[3] Boehringer Ingelheim GmbH & Co KG, Real World Evidence Analyt Ctr Excellence, Ridgefield, CT USA

[4] Changi Gen Hosp, Dept Infect Dis, Singapore, Singapore

[5] Orbital Therapeut, Cambridge, MA 02139 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

BNT162b2; mRNA vaccine; COVID-19; heterologous booster; inactivated virus vaccine; effectiveness; CORONAVAC; DELTA;

D O I：

10.1080/21645515.2023.2165856

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.

引用

页数：16

共 50 条

[41] The BNT162b2 mRNA Covid-19 vaccine does not impair sperm parameters [J].

Safrai, Myriam ;

Herzberg, Shmuel ;

Imbar, Tal ;

Reubinoff, Benjamin ;

Dior, Uri ;

Ben-Meir, Assaf .

REPRODUCTIVE BIOMEDICINE ONLINE, 2022, 44 (04) :685-688

[42] Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women [J].

Yeo, Kee Thai ;

Chia, Wan Ni ;

Tan, Chee Wah ;

Ong, Chengsi ;

Yeo, Joo Guan ;

Zhang, Jinyan ;

Poh, Su Li ;

Lim, Amanda Jin Mei ;

Sim, Kirsten Hui Zhi ;

Sutamam, Nursyuhadah ;

Chua, Camillus Jian Hui ;

Albani, Salvatore ;

Wang, Lin-Fa ;

Chua, Mei Chien .

FRONTIERS IN IMMUNOLOGY, 2022, 12

[43] Acute cervical dystonia following the BNT162b2 mRNA COVID-19 vaccine [J].

Algahtani, Hussein A. ;

Shirah, Bader H. ;

Alwafi, Emad .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 218

[44] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers [J].

Rojkovich, Bernadette ;

Nemeth, Dora ;

Torok, Eszter ;

Szabo, Bernadette ;

Pinter, Agnes ;

Juhasz, Istvan ;

Weidl, Marton ;

Lanyi, Eva ;

Pavel-Szecsko, Judit ;

Lazar, Imre ;

Perduk, Andras ;

Reiter, Jozsef ;

Nagy, Gyorgy ;

Nagy, Erzsebet ;

Geher, Pal .

ORVOSI HETILAP, 2021, 162 (39) :1551-1557

[45] The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout [J].

Zaqout, Ahmed ;

Daghfal, Joanne ;

Alaqad, Israa ;

Hussein, Saleh A. N. ;

Aldushain, Abdullah ;

Almaslamani, Muna A. ;

Abukhattab, Mohammed ;

Omrani, Ali S. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 108 :116-118

[46] Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis [J].

Chiara Pellicano ;

Roberta Campagna ;

Alessandra Oliva ;

Giorgia Leodori ;

Marzia Miglionico ;

Amalia Colalillo ;

Ivano Mezzaroma ;

Claudio Maria Mastroianni ;

Ombretta Turriziani ;

Edoardo Rosato .

Clinical Rheumatology, 2022, 41 :2755-2763

[47] Subacute thyroiditis after SARS-CoV-2 BNT162b2 vaccine in a multiple myeloma patient [J].

Alkis, Nihan ;

Baysal, Mehmet .

SAGE OPEN MEDICAL CASE REPORTS, 2022, 10

[48] BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity [J].

Vizcarra, Pilar ;

Haemmerle, Johannes ;

Velasco, Hector ;

Velasco, Tamara ;

Fernandez-Escribano, Marina ;

Vallejo, Alejandro ;

Casado, Jose L. .

VACCINE, 2021, 39 (51) :7367-7374

[49] Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis [J].

Pellicano, Chiara ;

Campagna, Roberta ;

Oliva, Alessandra ;

Leodori, Giorgia ;

Miglionico, Marzia ;

Colalillo, Amalia ;

Mezzaroma, Ivano ;

Mastroianni, Claudio Maria ;

Turriziani, Ombretta ;

Rosato, Edoardo .

CLINICAL RHEUMATOLOGY, 2022, 41 (09) :2755-2763

[50] Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine [J].

Saciuk, Yaki ;

Kertes, Jennifer ;

Stein, Naama Shamir ;

Zohar, Anat Ekka .

JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (01) :30-33

← 1 2 3 4 5 →